RxDoctor Payments Data

Olukemi Aina

Psychiatric/Mental Health · Melrose Park, ILNPI 1124787650

Payments from drug & device makers

$3,841in general payments, 2019–2025

Across 197 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$447
  • Otsuka America Pharmaceutical, Inc.$425
  • Neurocrine Biosciences, Inc.$403
  • Johnson & Johnson$401
  • Lundbeck LLC$374
  • plus $463 from 4 others

What the payments were for

  • Food & beverage$3,837100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,841 in reported general payments places this provider in the 90th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$7,459
Medicare patients
25
Services billed
117

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl23$39,076
AristadaAripiprazole Lauroxil14$32,590
Invega SustennaPaliperidone Palmitate13$27,185
Lurasidone Hcl13$15,558
InvegaPaliperidone12$3,803
Aripiprazole102$3,392
Clozapine28$1,332
Asenapine Maleate11$1,322
Divalproex Sodium49$1,114
Quetiapine Fumarate67$699
Duloxetine Hcl54$695
Olanzapine72$640
Bupropion XlBupropion Hcl36$569
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$496
Mirtazapine34$478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,329$39,07623 claims
Alkermes, Inc.Aristada$447$32,59014 claims
Johnson & JohnsonInvega Sustenna, Invega$401$30,98825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Melrose Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →